Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-center phase I/II safety and feasibility study using CliniMACS TCRα/β and CD19 depleted stem cell grafts from haploidentical donors for haematopoietic progenitor cell transplantation in children and adults

Trial Profile

A multi-center phase I/II safety and feasibility study using CliniMACS TCRα/β and CD19 depleted stem cell grafts from haploidentical donors for haematopoietic progenitor cell transplantation in children and adults

Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Apr 2019

At a glance

  • Drugs TCR alphabeta-CD19-depleted peripheral blood stem cell therapy (Primary)
  • Indications Acute myeloid leukaemia; Aplastic anaemia; Haematological malignancies; Hodgkin's disease; Leukaemia; Lysosomal storage diseases; Metabolic disorders; Multiple myeloma; Myelodysplastic syndromes; Neuroblastoma; Precursor cell lymphoblastic leukaemia-lymphoma; Sickle cell anaemia; Soft tissue sarcoma
  • Focus Therapeutic Use
  • Acronyms TCRalpha/beta-Haplo2010
  • Sponsors Miltenyi Biotec GmbH
  • Most Recent Events

    • 04 Dec 2018 Status changed to completed as per results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 12 Dec 2017 Results (n=30) assessing one year safety and efficacy follow-up, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top